Studies based on serum and cerebrospinal fluid biomarkers entail invasive procedures, rendering them less practical for schizophrenia patients, and markers like QAlb and S100b are non-specific, incapable of precisely mirroring BBB permeability changes. Here, S100B is linked to schizophrenia.